文献速递淋巴瘤

30个月时达到完全缓解的滤泡性淋巴瘤患者预期寿命与西班牙一般人群相似

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.
PubMed 文献 · Br J Haematol · 2019-02-22

该研究分析接受含利妥昔单抗方案治疗的滤泡性淋巴瘤患者30个月时完全缓解状态与预期寿命的关系,训练组263例中188例达CR30,其10年总生存率87%、相对生存率100%,与性别年龄匹配的西班牙一般人群无差异,并在GELTAMO独立队列693例中验证。

要点

  • 训练组中CR30患者10年总生存率为87%,非CR30患者为53%。
  • CR30患者10年相对生存率为100%,预期寿命与匹配的西班牙一般人群无差异。
  • FL国际预后指数是CR30组中预测总生存的最重要变量。

核心结论

  • 接受免疫化疗后30个月达到完全缓解的滤泡性淋巴瘤患者生存与性别年龄匹配的西班牙一般人群相似。

研究设计与样本

  • 训练组为10年期间连续诊断、需要治疗并接受含利妥昔单抗方案治疗的263例滤泡性淋巴瘤患者。
  • 验证队列为来自Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea(GELTAMO)组的693例滤泡性淋巴瘤独立队列。

主要发现

  • 训练组中188例患者处于CR30,非CR30与CR30患者的10年总生存率分别为53%和87%。
  • 训练组非CR30与CR30患者的10年相对生存率分别为73%和100%,CR30患者预期寿命未见下降。
  • 多因素分析显示滤泡性淋巴瘤国际预后指数是CR30组预测总生存的最重要变量。
  • CR30状态对相对生存的影响在GELTAMO独立队列中得到验证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of immunochemotherapy has improved the outcome of follicular lymphoma (FL). Recently, complete response at 30 months (CR30) has been suggested as a surrogate for progression-free survival. This study aimed to analyse the life expectancy of FL patients according to their status at 30 months from the start of treatment in comparison with the sex and age-matched Spanish general population (relative survival; RS). The training series comprised 263 patients consecutively diagnosed with FL in a 10-year period who needed therapy and were treated with rituximab-containing regimens. An independent cohort of 693 FL patients from the Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO) group was used for validation. In the training cohort, 188 patients were in CR30, with a 10-year overall survival (OS) of 53% and 87% for non-CR30 and CR30 patients, respectively. Ten-year RS was 73% and 100%, showing no decrease in life expectancy for CR30 patients. Multivariate analysis indicated that the FL International Prognostic Index was the most important variable predicting OS in the CR30 group. The impact of CR30 status on RS was validated in the independent GELTAMO series. In conclusion, FL patients treated with immunochemotherapy who were in CR at 30 months showed similar survival to a sex- and age-matched Spanish general population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Magnano L, Alonso-Alvarez S, Alcoceba M, et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol. 2019. PMID: 30793290. doi:10.1111/bjh.15805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。